Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has signed an agreement with Australia’s Nuclear Science and Technology Organisation (ANSTO) to supply the company with isotope non-carrier-added lutetium-177 (Lu-177) for its trials in Australia.
The isotope will be used by in combination with Radiopharm’s propriety nanobody in a Phase I therapeutic dose escalation trial in patients with non-small cell lung cancer. The trial is planned to start in Q1 2023 in collaboration with GenesisCare and ANSTO.
The agreement is effective from December 1, 2022.
ANSTO is committed to work that improves human health and saves lives through technologies for diagnostic, therapeutic and innovative treatments for current and emerging diseases,” said Shaun Jenkinson, CEO of ANSTO.
“We are excited that the isotopes we will supply to Radiopharm Theranostics will go toward expanding this vision at it seeks to revolutionise cancer treatment.”
About ANSTO
“ANSTO is one of Australia’s largest public research organisations and is widely recognised as an international leader in the field of nuclear science and technology,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.
“Partnering with ANSTO for the supply of lutetium-177 is an important step as we move forward on our trials in Australia.”
Australia’s Nuclear Science and Technology Organisation, (ANSTO) is the home of Australia’s most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.
[;ANSTO operates much of Australia’s landmark infrastructure including one of the world’s most modern nuclear research reactors, OPAL; a comprehensive suite of neutron beam instruments at the Australian Centre for Neutron Scattering; the Australian Synchrotron and the Centre for Accelerator Science.
